PART I – FINANCIAL INFORMATION This section presents the unaudited condensed consolidated financial statements and management's discussion and analysis [Financial Statements](index=5&type=section&id=Item%201.%20Financial%20Statements.) Bone Biologics, a development-stage medical device company, reported no revenue, a reduced net loss, and a going concern warning [Unaudited Condensed Consolidated Balance Sheets](index=5&type=section&id=Unaudited%20Condensed%20Consolidated%20Balance%20Sheets) The balance sheet highlights key financial positions including cash, total current assets, liabilities, and accumulated deficit Condensed Consolidated Balance Sheet Highlights (Unaudited) | Account | June 30, 2024 | December 31, 2023 | | :--- | :--- | :--- | | **Assets** | | | | Cash | $2,332,068 | $3,026,569 | | Total current assets | $3,193,464 | $3,737,763 | | **Liabilities & Equity** | | | | Total current liabilities | $284,507 | $831,402 | | Total stockholders' equity | $2,908,957 | $2,906,361 | | Accumulated deficit | $(82,558,661) | $(80,908,958) | [Unaudited Condensed Consolidated Statements of Operations](index=6&type=section&id=Unaudited%20Condensed%20Consolidated%20Statements%20of%20Operations) The statement of operations details revenues, R&D, G&A expenses, leading to loss from operations and net loss Condensed Consolidated Statements of Operations (Unaudited) | Metric | Three Months Ended June 30, 2024 | Three Months Ended June 30, 2023 | Six Months Ended June 30, 2024 | Six Months Ended June 30, 2023 | | :--- | :--- | :--- | :--- | :--- | | Revenues | $0 | $0 | $0 | $0 | | Research and development | $350,442 | $2,295,251 | $596,067 | $4,885,896 | | General and administrative | $459,223 | $744,617 | $1,117,135 | $1,301,509 | | **Loss from operations** | **$(809,665)** | **$(3,039,868)** | **$(1,713,202)** | **$(6,187,405)** | | **Net Loss** | **$(783,733)** | **$(1,769,238)** | **$(1,649,703)** | **$(5,479,137)** | | **Loss per share** | **$(0.67)** | **$(5.21)** | **$(1.80)** | **$(18.57)** | [Unaudited Condensed Consolidated Statements of Stockholders' Equity](index=7&type=section&id=Unaudited%20Condensed%20Consolidated%20Statements%20of%20Stockholders%27%20Equity) This statement outlines changes in stockholders' equity, including impacts from net loss, public offerings, and warrant exercises - For the six months ended June 30, 2024, total stockholders' equity slightly increased from **$2,906,361** to **$2,908,957**. This was driven by proceeds from a public offering and warrant exercises, which were largely offset by the net loss for the period[16](index=16&type=chunk) - In March 2024, the company raised approximately **$1.5 million** (net of offering costs) from the sale of common stock and pre-funded warrants[16](index=16&type=chunk)[56](index=56&type=chunk) [Unaudited Condensed Consolidated Statements of Cash Flows](index=9&type=section&id=Unaudited%20Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) The cash flow statement summarizes cash used in operating activities, provided by financing, and net decrease in cash Condensed Consolidated Statements of Cash Flows (Unaudited) | Cash Flow Activity | Six Months Ended June 30, 2024 | Six Months Ended June 30, 2023 | | :--- | :--- | :--- | | Net cash used in operating activities | $(2,199,276) | $(4,982,666) | | Net cash provided by financing activities | $1,504,775 | $4,452,163 | | **Net decrease in cash** | **$(694,501)** | **$(530,503)** | | **Cash, end of period** | **$2,332,068** | **$7,007,809** | [Notes to Unaudited Condensed Consolidated Financial Statements](index=10&type=section&id=Notes%20to%20Unaudited%20Condensed%20Consolidated%20Financial%20Statements) Key notes include details on reverse stock splits, warrant liabilities, license obligations, and subsequent events - The company executed two reverse stock splits: a **1-for-30** split on June 5, 2023, and a **1-for-8** split on December 20, 2023. All share and per-share amounts have been retroactively restated[30](index=30&type=chunk) - The company has a warrant liability of **$7,655** as of June 30, 2024, which is classified as a liability and re-measured at fair value each reporting period due to certain provisions in the warrants issued in October 2022[42](index=42&type=chunk)[51](index=51&type=chunk) - Under the license agreement with UCLA TDG, the company is obligated to make milestone payments, including **$100,000** upon enrollment of the first subject in a Feasibility Study, which was triggered during the six months ended June 30, 2024[75](index=75&type=chunk)[77](index=77&type=chunk) - Subsequent to the quarter end, on August 2, 2024, the company completed a warrant inducement transaction, generating net proceeds of approximately **$1.7 million**[28](index=28&type=chunk)[80](index=80&type=chunk) - The company is a medical device firm focused on bone regeneration using the NELL-1 protein, licensed exclusively from UCLA TDG. Its product is classified as a device/drug combination product requiring FDA pre-market approval[23](index=23&type=chunk) - The company has incurred an accumulated deficit of approximately **$82.6 million** since inception and has not generated any revenue. These factors, along with a net loss of **$1.6 million** and **$2.2 million** cash used in operations in the first six months of 2024, raise substantial doubt about its ability to continue as a going concern[26](index=26&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=22&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management attributes reduced net loss to lower R&D costs; cash expected to fund operations only into Q1 2025 - On June 20, 2024, the company announced the treatment of the first patient in its multicenter, prospective, randomized pilot clinical study of the NB1 bone graft device in Australia. The study will evaluate safety and effectiveness in **30 subjects** undergoing transforaminal lumbar interbody fusion (TLIF)[88](index=88&type=chunk)[89](index=89&type=chunk) Comparison of Operating Expenses (Three Months Ended June 30) | Expense Category | 2024 | 2023 | % Change | | :--- | :--- | :--- | :--- | | Research and development | $350,442 | $2,295,251 | (84.73)% | | General and administrative | $459,223 | $744,617 | (38.33)% | | **Total operating expenses** | **$809,665** | **$3,039,868** | **(73.37)%** | Comparison of Operating Expenses (Six Months Ended June 30) | Expense Category | 2024 | 2023 | % Change | | :--- | :--- | :--- | :--- | | Research and development | $596,067 | $4,885,896 | (87.80)% | | General and administrative | $1,117,135 | $1,301,509 | (14.17)% | | **Total operating expenses** | **$1,713,202** | **$6,187,405** | **(72.31)%** | - The significant decrease in R&D expenses in 2024 is attributed to the high costs incurred in 2023 for the production of the NELL-1 protein required for the initial clinical study[102](index=102&type=chunk)[107](index=107&type=chunk) - The company's cash of **$2.3 million** at June 30, 2024, supplemented by the **$1.7 million** from the August 2024 warrant inducement, is anticipated to cover operational needs only into the first quarter of 2025[116](index=116&type=chunk) [Quantitative and Qualitative Disclosures about Market Risk](index=28&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20about%20Market%20Risk) The company has indicated that this item is not applicable - Not applicable[119](index=119&type=chunk) [Controls and Procedures](index=28&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded disclosure controls and procedures were effective with no material changes to internal control - Management, including the CEO and CFO, evaluated the company's disclosure controls and procedures and concluded they were effective as of June 30, 2024[119](index=119&type=chunk) - No changes occurred in the internal control over financial reporting during the quarter ended June 30, 2024, that have materially affected, or are reasonably likely to materially affect, these controls[120](index=120&type=chunk) PART II – OTHER INFORMATION This section provides updates on legal proceedings, risk factors, equity sales, other information, and exhibits [Legal Proceedings](index=29&type=section&id=Item%201.%20Legal%20Proceedings) No material updates to legal proceedings previously disclosed in the company's Annual Report on Form 10-K or Q1 2024 Form 10-Q - There are no material updates to previously disclosed legal matters[121](index=121&type=chunk) [Risk Factors](index=29&type=page&id=Item%201A.%20Risk%20Factors) No material changes from the risk factors previously disclosed in the company's Annual Report on Form 10-K - Investors are referred to the risk factors section of the company's Annual Report on Form 10-K for the year ended December 31, 2023, as there have been no material changes[122](index=122&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=29&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) The company reported no unregistered sales of equity securities during the period - None[122](index=122&type=chunk) [Other Information](index=29&type=section&id=Item%205.%20Other%20Information) No director or officer adopted or terminated a Rule 10b5-1 trading arrangement during the second quarter of 2024 - No director or officer adopted or terminated a Rule 10b5-1 trading arrangement during the three months ended June 30, 2024[123](index=123&type=chunk) [Exhibits](index=30&type=section&id=Item%206.%20Exhibits) This section lists the exhibits filed with the Form 10-Q, including certifications by the Principal Executive Officer and Principal Financial Officer List of Exhibits | Exhibit Number | Description | | :--- | :--- | | 31.1 | CEO Certification (Section 302) | | 31.2 | CFO Certification (Section 302) | | 32.1 | CEO Certification (Section 906) | | 32.2 | CFO Certification (Section 906) | | 101.INS - 101.PRE | Inline XBRL Documents |

Company Overview - Bone Biologics Corporation is focused on developing orthobiologic products for spine fusion markets [1][3] - The company is engaged in regenerative medicine for bone and is working with strategic partners on preclinical research of the Nell-1 protein [3] Upcoming Event - The company's president and CEO, Jeffrey Frelick, and CFO, Deina Walsh, will participate in a "CEO Chat" on June 20, 2024, at the Life Science Investor Forum [1] - The interview will start at 11:00 a.m. Eastern time and will be accessible for investors to view [1][2] - Management will also hold one-on-one meetings with investors on the same day from 11:30 a.m. to 5:00 p.m. Eastern time [1] Investor Engagement - Investors are encouraged to preregister for the event to facilitate participation and receive updates [1] - A chat function will be available for investors to ask questions during the event [1] - The interview will be available for viewing on the company's website for 90 days post-event [2]

PART I – FINANCIAL INFORMATION [Financial Statements](index=5&type=section&id=Item%201.%20Financial%20Statements.) The company reported no revenue, a significantly reduced net loss, and an improved balance sheet, but faces substantial doubt about its ability to continue as a going concern [Unaudited Condensed Consolidated Balance Sheets](index=5&type=section&id=Unaudited%20Condensed%20Consolidated%20Balance%20Sheets) Total assets increased slightly to $3.84 million while total liabilities decreased significantly to $164,626 due to a legal settlement Condensed Consolidated Balance Sheet Data (Unaudited) | Account | March 31, 2024 | December 31, 2023 | | :--- | :--- | :--- | | **Assets** | | | | Cash | $3,227,634 | $3,026,569 | | Total current assets | $3,839,574 | $3,737,763 | | **Liabilities & Equity** | | | | Accounts payable and accrued expenses | $146,186 | $360,662 | | Accrued legal settlement | $0 | $414,989 | | Total liabilities | $164,626 | $831,402 | | Total stockholders' equity | $3,674,948 | $2,906,361 | [Unaudited Condensed Consolidated Statements of Operations](index=6&type=section&id=Unaudited%20Condensed%20Consolidated%20Statements%20of%20Operations) The company's Q1 2024 net loss improved to $0.9 million from $3.7 million year-over-year, driven by a 90.5% decrease in R&D expenses Condensed Consolidated Statements of Operations (Unaudited) | Metric | Three Months Ended March 31, 2024 | Three Months Ended March 31, 2023 | | :--- | :--- | :--- | | Revenues | $0 | $0 | | Research and development expenses | $245,625 | $2,590,645 | | General and administrative expenses | $657,911 | $556,892 | | Loss from operations | ($903,536) | ($3,147,537) | | Net loss | ($865,970) | ($3,709,899) | | Loss per share - basic and diluted | ($1.31) | ($55.20) | [Unaudited Condensed Consolidated Statements of Cash Flows](index=9&type=section&id=Unaudited%20Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) Net cash used in operations was $1.3 million, offset by $1.5 million from financing activities, resulting in a cash balance of $3.23 million Cash Flow Summary (Unaudited) | Cash Flow Activity | Three Months Ended March 31, 2024 | Three Months Ended March 31, 2023 | | :--- | :--- | :--- | | Net cash used in operating activities | ($1,303,411) | ($1,349,993) | | Net cash provided by financing activities | $1,504,476 | $0 | | Net increase (decrease) in cash | $201,065 | ($1,349,993) | | Cash, end of period | $3,227,634 | $6,188,319 | [Notes to Unaudited Condensed Consolidated Financial Statements](index=10&type=section&id=Notes%20to%20Unaudited%20Condensed%20Consolidated%20Financial%20Statements) Notes detail the company's 'Going Concern' issue, with cash reserves of $3.2 million only funding operations through Q3 2024 - The company is a medical device company focused on bone regeneration using the NELL-1 protein, licensed exclusively from UCLA TDG, which requires FDA pre-market approval[25](index=25&type=chunk) - The company has an **accumulated deficit of approximately $81.8 million** and incurred a net loss of **$0.9 million in Q1 2024**, raising substantial doubt about its ability to continue as a going concern[29](index=29&type=chunk) - Cash on hand of **$3.2 million** as of March 31, 2024, is expected to fund operations only through the **third quarter of 2024**, with estimated operating expenditures for the next twelve months at **$6.9 million**[29](index=29&type=chunk)[30](index=30&type=chunk) - The company is obligated to make future milestone payments to UCLA TDG, including **$250,000** upon Pivotal Study enrollment, **$500,000** upon Pre-Market Approval, and **$1,000,000** upon First Commercial Sale[75](index=75&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=20&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses reduced R&D expenses, a significant 'going concern' warning, and the need for an estimated $29 million to potentially achieve FDA approval [Results of Operations](index=23&type=section&id=Results%20of%20Operations) Q1 2024 operating expenses fell 71.3% due to lower R&D costs, resulting in a net loss improvement to $0.9 million from $3.7 million in Q1 2023 Operating Expenses Comparison (Q1 2024 vs Q1 2023) | Expense Category | Q1 2024 | Q1 2023 | Change (%) | | :--- | :--- | :--- | :--- | | Research and development | $245,625 | $2,590,645 | (90.52)% | | General and administrative | $657,911 | $556,892 | 18.14% | | **Total operating expenses** | **$903,536** | **$3,147,537** | **(71.29)%** | - The **significant decrease in R&D costs** is attributed to high expenses in 2023 for the production of the NELL-1 protein required for the initial clinical study[104](index=104&type=chunk) - The **increase in G&A costs** is mainly attributed to legal expenses related to settling ongoing litigation[105](index=105&type=chunk) [Liquidity and Capital Resources](index=24&type=section&id=Liquidity%20and%20Capital%20Resources) The company faces significant liquidity challenges, with $3.2 million in cash expected to last only through Q3 2024 despite a recent $1.5 million offering - The company has incurred **accumulated losses of $81.8 million** and its ability to continue as a **going concern is in substantial doubt**[108](index=108&type=chunk) - Cash of **$3,227,634** at March 31, 2024, is expected to fund operations through the **third quarter of 2024**[111](index=111&type=chunk) - The company anticipates needing approximately **$5 million** to complete first-in-man studies and an additional **$24 million** to achieve FDA approval[111](index=111&type=chunk) - A public offering on March 6, 2024, provided **net proceeds of $1,504,476**[109](index=109&type=chunk)[112](index=112&type=chunk) [Quantitative and Qualitative Disclosures about Market Risk](index=25&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20about%20Market%20Risk) The company states that this item is not applicable - Not applicable[114](index=114&type=chunk) [Controls and Procedures](index=25&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded that disclosure controls and procedures were effective as of March 31, 2024, with no material changes to internal controls - Based on an evaluation as of March 31, 2024, the Chief Financial Officer and Chief Executive Officer concluded that the company's **disclosure controls and procedures were effective**[115](index=115&type=chunk) - **No changes in internal control over financial reporting** occurred during the quarter ended March 31, 2024, that have materially affected, or are reasonably likely to materially affect, internal controls[116](index=116&type=chunk) PART II – OTHER INFORMATION [Legal Proceedings](index=26&type=section&id=Item%201.%20Legal%20Proceedings) The company settled a lawsuit for a total of $750,000, paying $414,989 out-of-pocket, leading to the case's dismissal - The company entered into a Settlement Agreement on January 10, 2024, to resolve a lawsuit involving claims of breach of contract and tortious interference[117](index=117&type=chunk) - Under the agreement, the company agreed to a total payment of **$750,000** to the plaintiffs, paying **$414,989** of this amount on February 7, 2024, with the remainder covered by its insurance carrier[117](index=117&type=chunk) [Risk Factors](index=26&type=section&id=Item%201A.%20Risk%20Factors) No material changes to risk factors have occurred since the last Annual Report on Form 10-K - There have been **no material changes** from the risk factors as previously disclosed in the Annual Report on Form 10-K for the year ended December 31, 2023[118](index=118&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=26&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) The company reports no unregistered sales of equity securities or use of proceeds during the period - None[118](index=118&type=chunk) [Other Information](index=26&type=section&id=Item%205.%20Other%20Information) No directors or officers adopted or terminated Rule 10b5-1 trading arrangements during the first quarter of 2024 - No director or officer adopted or terminated a "Rule 10b5-1 trading arrangement" or "non-Rule 10b5-1 trading arrangement" during the three months ended March 31, 2024[119](index=119&type=chunk) [Exhibits](index=27&type=section&id=Item%206.%20Exhibits) The report includes exhibits such as warrant forms, purchase agreements, and amended executive employment agreements - Exhibits filed include forms of Warrants, Pre-Funded Warrants, and Placement Agent Warrants from the **March 6, 2024 offering**[121](index=121&type=chunk) - An Amended and Restated Employment Agreement for CEO Jeffrey Frelick and an amendment to the Employment Agreement for CFO Deina Walsh are included as exhibits[121](index=121&type=chunk)

Core Viewpoint - Bone Biologics Corporation has successfully closed a public offering, raising approximately $2.0 million through the sale of 781,251 shares of common stock and accompanying warrants, aimed at funding clinical trials and other corporate purposes [1][2]. Group 1: Offering Details - The public offering consisted of 781,251 shares of common stock priced at $2.56 per share, along with warrants to purchase an equal number of shares at an exercise price of $2.43, which are exercisable immediately and will expire in five years [1][2]. - H.C. Wainwright & Co. served as the exclusive placement agent for this offering [1]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for funding clinical trials, maintaining and extending the patent portfolio, and for working capital and other general corporate purposes [2]. Group 3: Company Background - Bone Biologics focuses on regenerative medicine for bone, particularly in spinal fusion procedures, and is developing a bone graft substitute product based on preclinical research of the Nell-1 protein [4].

Core Viewpoint - Bone Biologics Corporation has announced a public offering of 781,251 shares of common stock at a price of $2.56 per share, along with warrants to purchase an equal number of shares, aiming to raise approximately $2.0 million for clinical trials and other corporate purposes [1][2]. Group 1: Offering Details - The public offering includes 781,251 shares of common stock and warrants, priced at $2.56 per share, with warrants having an exercise price of $2.43, exercisable immediately and expiring in five years [1][2]. - The expected gross proceeds from the offering are approximately $2.0 million before deducting fees and expenses [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized to fund clinical trials, maintain and extend the patent portfolio, and for working capital and other general corporate purposes [2]. Group 3: Company Background - Bone Biologics focuses on regenerative medicine for bone, particularly in spinal fusion procedures, and is developing a bone graft substitute product based on preclinical research of the Nell-1 protein [5].

Core Viewpoint - Bone Biologics Corporation is advancing its product candidate NB1 into human clinical testing for spinal fusion, with three hospital sites engaged for a pilot clinical trial evaluating its safety and effectiveness in treating degenerative disc disease [1][2]. Company Overview - Bone Biologics Corporation focuses on regenerative medicine for bone, particularly through its NB1 bone graft device, which is designed for spinal fusion procedures and has potential applications in trauma and osteoporosis [5]. Product Details - NB1 is a recombinant human protein (rhNELL-1) combined with demineralized bone matrix, aimed at enhancing bone regeneration and healing, especially in challenging cases [3]. - The mechanism of action for rhNELL-1 involves receptor binding and intracellular signaling to promote osteogenic gene expression and bone formation [3]. Market Opportunity - The global market for bone graft substitutes in spine fusion is estimated at $3 billion annually, with additional long-term opportunities in the $11 billion market for osteoporosis treatment and the $8 billion market for trauma treatment [4].

As filed with the Securities and Exchange Commission on February 26, 2024 Registration Statement No. 333-276771 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO. 2 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Delaware 2834 42-1743430 (I.R.S. Employer Identification Number) 2 Bu ...

Registration Statement No. 333-276771 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO. 1 As filed with the Securities and Exchange Commission on February 23, 2024 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BONE BIOLOGICS CORPORATION (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Delaware 2834 42-1743430 (I.R.S. Employer ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common stock, $0.001 par value per share BBLG The Nasdaq Capital Market Warrants to Purchase Common stock, $0.001 par value per share BBLGW The Nasdaq Capital Market Emerging growth company ☐ FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2023 ☐ TRANSITION REPORT PURSUA ...

As filed with the Securities and Exchange Commission on January 30, 2024 Registration Statement No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER (Primary Standard Industrial Classification Code Number) THE SECURITIES ACT OF 1933 BONE BIOLOGICS CORPORATION (Exact name of registrant as specified in its charter) Delaware 2834 42-1743430 (I.R.S. Employer Identification Number) 2 Burlington Woods Drive, Suite 100 Burlington, MA 01803 (781) 552 ...